ArticleFunctional & integrative genomics2026
A multi-region transcriptomic framework reveals global and region-specific ubiquitin-proteasome system biomarkers in Alzheimer's disease.
Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The involvement of ubiquitin-proteasome system (UPS) impairment in Alzheimer's disease (AD) is increasing gradually yet the molecular organization of the system throughout the AD brain is poorly understood, as is the distribution of molecular markers. To systemically identify UPS-associated molecular signatures, we carried out a multi-region transcriptomic analysis of six different brain regions in AD patients and age-matched controls. The molecular perturbation of regions recapitulated the known regional vulnerability hierarchy with significant changes observed in the entorhinal cortex and hippocampus as well as middle temporal gyrus and posterior cingulate. A synchronized downregulation of UPS components was observed in the vulnerable regions indicating towards the extensive dysfunction of ubiquitin-mediated protein surveillance and proteasomal degradation. The consistent features associated with UPS disruption were linked with synaptic dysfunction, mitochondrial impairment and loss of proteostatic homeostasis as revealed by the functional analyses. We formulated a framework based on composite prioritization which combined several aspects like differential expression, network topology, regional consistency and diagnostic performance for the purpose of identifying strong biomarker candidates. The analysis revealed the most eminent global biomarkers of AD associated with UPS, namely, PSMB4, SNCA, PSMB7, PSMD1, and UBE3A. UBE2R1 (CDC34) was used to define region-specific biomarker signatures in the entorhinal cortex, UBC in the hippocampus, PSMA3 in middle temporal gyrus, PSMD4 in posterior cingulate cortex and UBE2V2 in superior frontal gyrus. These exploratory results provide the first systems-level biomarker atlas of UPS dysfunction in distinct AD brain regions and suggest that there are potential global and region-specific UPS signatures that could be used in diagnostics and drug development.
Indexed as
Identifiers
42809130What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.